Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable Esophageal Squamous Cell Carcinoma A Prospective, Single-Center, Open Label Phase II Cohort Study WATCHER
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms WATCHER
Most Recent Events
- 23 Aug 2022 New trial record